These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6469433)

  • 21. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure.
    Jackson EK; Dubinion JH; Mi Z
    Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):29-34. PubMed ID: 18047624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.
    Oates HF; Stoker LM
    Clin Exp Pharmacol Physiol; 1981; 8(2):133-9. PubMed ID: 7018762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension.
    Kingswood JC; Harrison PR; Banks RA; Higgs E; Mackenzie JC
    Postgrad Med J; 1983; 59 Suppl 3():173-6. PubMed ID: 6647204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function.
    Boehringer K; Weidmann P; Link L; Bianchetti MG; Schiffl H; Reubi FC
    Br J Clin Pharmacol; 1983 Feb; 15(2):181-8. PubMed ID: 6133543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
    Chazan BI; Duff DA; McCallum A; Whaley K
    Curr Med Res Opin; 1986; 10(3):150-8. PubMed ID: 2873966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic effects of the arteriolar vasodilators hydralazine, dihydralazine and endralazine in the conscious spontaneously hypertensive rat.
    Struyker-Boudier HA; van Essen H; Smits JF
    Eur J Pharmacol; 1983 Nov; 95(3-4):151-9. PubMed ID: 6653667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-moderate hypertension. Manidipine Efficacy in Long-Term Treatment Group.
    Fogari R; Zoppi A; Lusardi P; Mugellini A
    Blood Press Suppl; 1996; 5():24-8. PubMed ID: 8973789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A dose-finding study of the combination of pindolol, clopamide and endralazine in the treatment of moderate-to-severe hypertension.
    Seedat YK; Rawat R
    S Afr Med J; 1984 Nov; 66(18):682-4. PubMed ID: 6387966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of an active cadralazine metabolite in plasma and blood vessels of spontaneously hypertensive rats.
    Terauchi Y; Watari S; Ishikawa S; Takeyama K; Sekine Y; Hashimoto M; Hayashi T
    Arzneimittelforschung; 1988 Feb; 38(2):237-9. PubMed ID: 3370071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Autoradiographic studies of the distribution of 14C-endralazine in the mouse].
    Kindler J; Mödder G; Sieberth HG
    Arzneimittelforschung; 1985; 35(3):599-602. PubMed ID: 4039585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihypertensive effects of the calcium antagonistic agent nifedipine.
    Maeda K; Tanaka C; Tsukano Y; Minamikawa H; Komatsu H; Kotsumi K; Inoue E
    Arzneimittelforschung; 1982; 32(3):267-71. PubMed ID: 7200785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Chu KM; Shieh SM; Hu OY
    Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects.
    O'Shaughnessy KM; Fu B; Dickerson C; Thurston D; Brown MJ
    Clin Sci (Lond); 2000 Sep; 99(3):233-8. PubMed ID: 11787477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of bisoprolol and acebutolol on resting blood pressure and on exercise blood pressure profile in hypertensive patients: a comparative, single-blind study.
    Bouvier JM; Rabot D; Herrero G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S179-83. PubMed ID: 11527124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of oxdralazine and dihydralazine in essential hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza W; Criscuolo D
    Int J Clin Pharmacol Ther Toxicol; 1981 Aug; 19(8):372-6. PubMed ID: 7030978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.